IPSEN S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.38 USD | -0.26% |
|
+2.38% | +3.05% |
| 07-11 | CAC40: maintains gains after reassuring US inflation figures | CF |
| 07-11 | CAC40: rise without volume, W-Street at its zenith but falls back | CF |
Business Summary
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Number of employees: 5,325
Sales per Business
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Oncology
75.2
%
| 2,380 | 78.7 % | 2,351 | 75.2 % | -1.19% |
Neurosciences
21.1
%
| 604 | 20.0 % | 659 | 21.1 % | +9.08% |
Rare Diseases
3.7
%
| 41 | 1.4 % | 117 | 3.7 % | +184.43% |
Sales per region
| EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Europe
40.2
%
| 1,237 | 40.9 % | 1,257 | 40.2 % | +1.56% |
North America
33.3
%
| 1,032 | 34.1 % | 1,042 | 33.3 % | +0.94% |
Rest of the World
26.5
%
| 756 | 25.0 % | 829 | 26.5 % | +9.73% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 57 | 20-06-30 |
| Director of Finance/CFO | 55 | 14-11-02 | |
| Chairman | 66 | 10-11-21 | |
Sandra Silvestri
CTO | Chief Tech/Sci/R&D Officer | 50 | 23-05-04 |
| Chief Tech/Sci/R&D Officer | 57 | 23-09-21 | |
Aidan Murphy
CTO | Chief Tech/Sci/R&D Officer | 58 | 17-12-31 |
Craig Marks
IRC | Investor Relations Contact | - | - |
| Corporate Officer/Principal | - | 22-02-28 | |
| Corporate Officer/Principal | - | 20-09-30 | |
| Corporate Officer/Principal | 50 | 21-10-31 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Margaret Liu
BRD | Director/Board Member | 67 | 17-06-06 |
Karen Witts
BRD | Director/Board Member | 61 | 22-01-20 |
Michèle Ollier
BRD | Director/Board Member | 66 | 15-05-26 |
Henri Beaufour
BRD | Director/Board Member | 59 | 05-08-29 |
Antoine Flochel
BRD | Director/Board Member | 59 | 05-08-29 |
Carol Xueref
BRD | Director/Board Member | 67 | 12-05-31 |
| Director/Board Member | 54 | 20-05-31 | |
David Loew
CEO | Chief Executive Officer | 57 | 20-06-30 |
| Director/Board Member | 45 | 20-11-05 | |
Naomi Binoche
BRD | Director/Board Member | - | - |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 83,814,526 | 34,829,283 ( 41.56 %) | 1,116,316 ( 1.332 %) | 41.56 % |
Holdings
Company contact information
Group companies
| Name | Category and Sector |
|---|---|
Socapharma SAS
| |
Ipsen Pharma Biotech SAS
 Ipsen Pharma Biotech SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma Biotech SAS engages in the pharmaceutical industry. It offers drugs to treat neurology, endocrinology, uro-oncology, hematology, gastroenterology, cardiovascular, and cognitive disorders. The company is headquartered in Signes, France. |
Pharmaceuticals: Major
|
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. |
Pharmaceuticals: Major
|
Sector
Sales per Business
Sales per region
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
111.2
EUR
Average target price
127.3
EUR
Spread / Average Target
+14.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.35% | 815B | |
| +32.19% | 597B | |
| -0.10% | 377B | |
| +15.47% | 319B | |
| +13.10% | 310B | |
| +16.17% | 247B | |
| +14.09% | 228B | |
| +16.54% | 180B | |
| +4.31% | 170B |
- Stock Market
- Equities
- IPN Stock
- IPSEY Stock
- Company Ipsen S.A.
